| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03113084 Details | 2019-10-14 Interventional | 1 | - | Calcium heparin Heparin Heparin | Delay in the R&D stage - | |||
| NCT02034916 2013-003076-12 Details | 2019-10-14 Interventional | 2 | 84 | Talazoparib Breast Neoplasm… BRCA 1 Gene Mut… BRCA 2 Gene Mut… | Primary Analysis and study completed. Not stopped due to safety concerns. - | |||
| NCT03904849 Details | 2019-10-11 Interventional | 1/2 | 0 | Cannabidiol Alcohol Drinkin… Alcoholism Alcohol Use Dis… | This study was intended to produce pilot data for a center grant component that will no longer
be conducted. - | |||
| NCT00422201 Details | 2019-10-11 Interventional | 2 | 18 | Mifepristone Cardiac Complex… Cushing Syndrom… Syndrome Cushing's Syndr… | - As a consequence of the premature study end, analyses performed were primarily descriptive due to the reduced number of enrolled and completed patients. | |||
| NCT02776891 Details | 2019-10-10 Interventional | 2 | 0 | Citric Acid Gallium citrate Sodium Citrate Burkitt Lymphom… Lymphoma Lymphoma, Large… | Unexpected dose production issues prevented study start up - | |||
| NCT02729961 Details | 2019-10-10 Interventional | 1/2 | 0 | Antibodies Antibodies, Mon… Antineoplastic … Brentuximab Ved… Ceritinib Immunoconjugate… Immunoglobulins Lymphoma Lymphoma, Large… Lymphoma, Non-H… Anaplastic Larg… CD30-Positive N… Systemic Anapla… | Administrative closure - | |||
| NCT01390220 2011-001318-32 Details | 2019-10-10 Interventional | 3 | 292 | Midazolam Epilepsy Seizures | - - | |||
| NCT01239342 Details | 2019-10-10 Interventional | 2 | 43 | Everolimus Carcinoma Carcinoma, Rena… Kidney Neoplasm… Metastatic Kidn… Recurrent Renal… Stage III Renal… Stage IV Renal … | - - | |||
| NCT03296098 Details | 2019-10-09 Interventional | 2 | - | Ulipristal acet… Contraception Healthy Female | Awaiting FDA approval to continue - | |||
| NCT02972866 Details | 2019-10-09 Interventional | 3 | 0 | Budesonide Rhinitis Rhinitis, Aller… Rhinitis, Aller… | Regulatory strategy - | |||
| NCT02111096 2013-004275-12 Details | 2019-10-09 Interventional | 2 | 174 | Metformin Sitagliptin Pho… Diabetes Mellit… Diabetes Mellit… | The overall benefit-risk profile did not support continued development of LY2409021 for type 2
diabetes. Terminated, The overall benefit-risk profile did not support continued development of LY2409021 for type 2 diabetes. | |||
| NCT02076594 2011-005537-39 Details | 2019-10-09 Interventional | 3 | 171 | Capecitabine Docetaxel Epirubicin Oxaliplatin Stomach Neoplas… Locally Advance… Metastatic Gast… | The interim analysis performed on 09 November 2018, showed the failure to achieve the primary
objective of effectiveness of the experimental treatment. - | |||
| NCT02072096 2013-001473-24 Details | 2019-10-09 Interventional | 4 | 192 | Acarbose Exenatide Glimepiride Insulin Glargin… Linagliptin Liraglutide Metformin Pioglitazone Sitagliptin Pho… Diabetes Mellit… Diabetes Mellit… | The trial was terminated per protocol because of lack of feasibility. The trial was terminated per protocol due to lack of feasibility. All participants completed the first 24 weeks of the study. Some participants continued into the Core study. Data was assessed from Baseline to last participant visit, up to 72 weeks. | |||
| NCT01545817 Details | 2019-10-09 Interventional | 2 | 74 | Everolimus Carcinoma Carcinoma, Rena… | As the therapeutic landscape in renal cell carcinoma is changing, it has become apparent that
information gained so far by CATChEz study is sufficient. the trial terminated early because the information gained from this study was sufficient to meet the objectives for which the study had been set up and would be no longer clinically relevant for the second-line management of RCC patients. | |||
| NCT03104816 Details | 2019-10-08 Interventional | 4 | 28 | Acetaminophen Hydromorphone Fusion of Spine… | Could not get an approval from Department Reviewer for the study continuation. The trial was not completed and had very small amount of participants. | |||
| NCT02968901 Details | 2019-10-08 Interventional | 4 | 46 | Macitentan Tadalafil Familial Primar… Hypertension Pulmonary Arter… | - - | |||
| NCT02227784 Details | 2019-10-08 Interventional | 3 | 366 | Atorvastatin Evacetrapib Ezetimibe Hyperlipidemias Hyperlipoprotei… Hyperlipidemia | Study termination due to program termination. Early termination was due to program termination. | |||
| NCT01683656 Details | 2019-10-08 Interventional | 4 | 4 | Niacin Atherosclerosis HIV | Withdrawal of IMP from the market. Data on risk-benefit ratio pending. - | |||
| NCT01352663 Details | 2019-10-08 Interventional | 3 | 0 | Insulin Insulin Glargin… Diabetes Mellit… Type I Diabetes | Business strategy decision - | |||
| NCT01332331 2010-019547-19 Details | 2019-10-08 Interventional | 2 | 41 | Ambrisentan Hypertension Hypertension, P… Pulmonary Arter… | Ongoing juvenile rat toxicology studies. - |